STAT1 and glioma: IGFBP2 regulates glioma progression by activating EGFR-STAT3 signaling and promoting cell proliferation and chemoresistance via the integrin β1-ERK pathway, whereas IGFBP3-STAT1 activation is associated with neoplastic cell invasion and poor patient outcomes44–46.